New stem cell filter could cut transplant complications in blood cancer patients
NCT ID NCT06047886
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new automated method (CliniMACS Prodigy) to select CD34 stem cells for patients with blood cancers who need a stem cell boost or second transplant. The goal is to reduce the risk of severe graft-versus-host disease (GVHD) while improving blood cell recovery. About 50 participants with conditions like AML, ALL, or MDS will be enrolled. The approach aims to make the cell-processing procedure simpler and safer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294-3300, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Dual-Action pill tame bone marrow tumors?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a new pill shrink the spleen in myelofibrosis?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?